October 2026
Largest Biopharmaceuticals Public Companies in Ireland
Benchmark revenue and EBITDA valuation multiples for public comps like
Jazz Pharmaceuticals, GH Research, Uniphar, Prothena Corp. and Iterum Therapeutics.
 | Jazz Pharmaceuticals is a biopharmaceutical company with corporate headquarters in Dublin, Ireland. It develops and commercializes medicines principally in neuroscience and oncology, with research programs ranging from early development through later clinical stages. Its neuroscience business includes treatments for sleep disorders and epilepsy. Its oncology activities address blood cancers and solid tumors, including patient populations with limited treatment options. The company combines internal research and development with acquisitions and partnerships that add medicines and development candidates to its portfolio. Commercial revenue is generated primarily from sales of approved pharmaceutical products. Jazz also maintains manufacturing and business operations in multiple countries to support development and supply. Its portfolio includes medicines obtained through the acquisition of GW Pharmaceuticals, including the epilepsy treatment Epidiolex. | $217 | +58% | $14B | $16B | 3.8x | 61.8x | ||
| GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. | $20 | +40% | $1.4B | $1B | - | (19.1x) | ||
| Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies. | $4 | -3% | $1.1B | $1.6B | 0.5x | 12.1x | ||
| Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others. | $8 | -21% | $433M | $152M | 15.7x | (0.7x) | ||
| Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. | $0 | -100% | $0K | $23M | - | (1.0x) | ||
| Median | $8 | -3% | $1.1B | $1B | 3.8x | (0.7x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.